Evaluation of contributors to amide proton transfer – weighted imaging and nuclear Overhauser enhancement – weighted imaging contrast in tumors at a high magnetic field
Magnetic Resonance in Medicine · 2023
DOI: 10.1002/mrm.29675 ↗Kurz gefasst
Fachartikel in der Zeitschrift Magnetic Resonance in Medicine, 2023. Verfasst von Jing Cui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University Institute of Imaging Science, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Brain Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
Purpose
The purpose is to evaluate the relative contribution from confounding factors (T 1 weighting and magnetization transfer) to the CEST ratio (CESTR)–quantified amide proton transfer (APT) and nuclear Overhauser enhancement (NOE) (−3.5) in tumors as well as whether the CESTR can reflect the distribution of the solute concentration ( f s ).
Methods
We first provided a signal model that shows the separate dependence of CESTR on these confounding factors and the clean CEST/NOE effects quantified by an apparent exchange‐dependent relaxation (AREX) method. We then measured the change in these effects in the 9‐L tumor model in rats, through which we calculated the relative contribution of each confounding factor. f s was also fitted, and its correlations with the CESTR and AREX were assessed to evaluate their capabilities to reflect f s .
Results
The CESTR‐quantified APT shows “positive” contrast in tumors, which arises primarily from R 1w at low powers and both R 1w and magnetization transfer at high powers. CESTR‐quantified NOE (−3.5) shows no or weak contrast in tumors, which is due to the cancelation of R 1w and NOE (−3.5), which have opposite contributions. CESTR‐quantified APT has a stronger correlation with APT f s than AREX‐quantified APT. CESTR‐quantified NOE (−3.5) has a weaker correlation with NOE (−3.5) f s than AREX‐quantified NOE (−3.5).
Conclusion
CESTR reflects a combined effect of T 1 weighting and CEST/NOE. Both factors depend on f s , which contributes positively to the dependence of CESTR on f s in APT imaging and enhances its correlation with f s . In contrast, these factors have opposite contributions to its dependence on f s in NOE (−3.5) imaging, thereby weakening the correlation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt University Institute of Imaging Science, Nashville, Tennessee, USA.
- Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Chemistry, University of Florida, Gainesville, Tennessee, USA.
- Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA.
- Department of Physics and Astronomy, Vanderbilt University, Nashville, Tennessee, USA.
ORCID-Profile: Jing Cui, Yu Zhao, Casey Sun, Junzhong Xu, Zhongliang Zu
Förderung
- NIBIB NIH HHS
- NIH HHS
- NIAMS NIH HHS
- National Institutes of Health
Zitieren
APA
Cui, J., Zhao, Y., Sun, C., Xu, J., & Zu, Z. (2023). Evaluation of contributors to amide proton transfer – weighted imaging and nuclear Overhauser enhancement – weighted imaging contrast in tumors at a high magnetic field. Magnetic Resonance in Medicine. https://doi.org/10.1002/mrm.29675
Vancouver
Cui J, Zhao Y, Sun C, Xu J, Zu Z. Evaluation of contributors to amide proton transfer – weighted imaging and nuclear Overhauser enhancement – weighted imaging contrast in tumors at a high magnetic field. Magnetic Resonance in Medicine. 2023. doi:10.1002/mrm.29675
BibTeX
@article{Cui2023,
author = {Cui, Jing and Zhao, Yu and Sun, Casey and Xu, Junzhong and Zu, Zhongliang},
title = {Evaluation of contributors to amide proton transfer – weighted imaging and nuclear Overhauser enhancement – weighted imaging contrast in tumors at a high magnetic field},
journal = {Magnetic Resonance in Medicine},
year = {2023},
doi = {10.1002/mrm.29675}
}
EUVIMED